MICVO’s Response Rate Slipped — and So Did PYXS
Confirmed responses fell from 46% (n=13) to 36% (12/33). Data beat old 2L chemo rates, yet safety, distant catalysts and financing overhang hit the stock.
/ 4 items
#PYXS↓
Wells Fargo Initiates Coverage of Pyxis Oncology with $12 Target, Sees Shares Doubling on Fall Update
Dose cap de-risks MICVO as Wells Fargo starts Pyxis at Overweight with $12 target. Sees at least 2x upside on fall HNSCC update.
Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
Pyxis Oncology's MICVO Shows Promise But Raises Concerns
Pyxis stock plunged 45% despite positive cancer drug results. Small patient sample, safety issues, and 2026 data timeline worried investors.